COMPARE · Data as of August 27, 2026
AUPH vs ELVN
Verdict: Side-by-side breakdown using the Bull Rankings model. AUPH scored 72.8, ELVN scored 19.3 — AUPH leads.
Compare another set
AUPH
Aurinia Pharmaceuticals Inc.
72.8
$16.75 · $2.2B
fundamentals as of
Score gap
53.5
AUPH leads
ELVN
Enliven Therapeutics, Inc.
19.3
$60.50 · $4.4B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Strongest balance sheetELVN0.00
- Highest qualityAUPH74 / 100
- Largest discount to fair valueAUPH-8%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
AUPH
stronger →← stronger
ELVN
74
Qualityreturns · margins · balance sheet
23
60
Growthrevenue & earnings expansion
10
87
Valuevaluation vs sector peers
31
AUPH is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
AUPH
ELVN
$175mC
FCF
-$67mF
+20.4%A-
Rev
—
0.10B+
D/E
0.00A
7.3xA
P/E
—
0.57A-
PEG
—
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
AUPH
ELVN
8% below
Price vs fair valuelower is cheaper
—
~6%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
-4%
1-yr DCF upside
—
+9%
5-yr DCF upside
—
+29%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AUPH
Why this score
- Earnings outpace cash
ELVN
Why this score
- Diluting shareholders
The companies
AUPHAurinia Pharmaceuticals Inc.
Why now
Biotechnology · market cap $2.2b. 13% off the 52-week high of $19.25. Revenue growing +20%, comfortably above the S&P median. PEG 0.57 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $17.86 (implying +7% upside).
Moat
ROE 51% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Beta 1.40 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ELVNEnliven Therapeutics, Inc.
Why now
Biotechnology · market cap $4.4b. Trading near 52-week high of $62.32 — momentum setup, limited technical margin of safety. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $73.90 (implying +22% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$67m) — capital raises or debt issuance likely required; dilution / leverage risk. Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. ROE -12% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where AUPH and ELVN diverge
On the headline score the gap is 53.5 points in favor of AUPH. The widest single difference is Value, where AUPH leads by 55.6 points.
- ValueAUPH 86.6 · ELVN 31.0AUPH +55.6
- QualityAUPH 74.0 · ELVN 23.2AUPH +50.8
- GrowthAUPH 60.3 · ELVN 10.0AUPH +50.3
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.